Novartis's Piqray Gets Europe Green Light At Last
First-In-Class PI3K inhibitor Approved For Breast Cancer
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
